Glioblastoma Pipeline Summary

DelveInsight’s, “Glioblastoma - Pipeline Insight, 2026” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Glioblastoma: Understanding

Glioblastoma: Overview

Glioblastoma multiforme (GBM) is the most aggressive and prevalent form of glioma, accounting for about 45% of primary malignant brain and CNS tumors in adults. MRI typically reveals irregularly defined lesions with central necrosis (T1 hypointensity) and peripheral edema (T2/FLAIR hyperintensity), while MR spectroscopy shows a choline peak. Definitive diagnosis relies on histopathology, showing pleomorphic astrocytic cells with high mitotic activity, microvascular proliferation, and necrosis. Immunohistochemistry often reveals positivity for GFAP, vimentin, and S100, with variable Ki-67 indices; additional testing includes IDH mutation and MGMT promoter methylation status. GBM remains largely incurable, with a median survival of 15 months and only 5.5% of patients surviving five years. It is classified into IDH wild-type and mutant forms wild-type GBM (about 90%) typically arises de novo in patients over 55 years and is linked to EGFR, TERT, and MGMT alterations, whereas IDH-mutant GBM, often evolving from lower-grade astrocytomas, is associated with ATRX and TP53 mutations, occurs in younger individuals, and confers a relatively better prognosis.

The primary established risk factor for glioblastoma (GBM) is high-dose ionizing radiation, with studies showing a 17% prevalence among patients who received prior therapeutic irradiation, and latency periods ranging from a few years to several decades. Conversely, allergies and atopic diseases appear to confer a low risk, while short-term use (under 10 years) of anti-inflammatory medications may offer modest protective effects. There is no strong evidence linking GBM to lifestyle factors such as smoking, alcohol, drug use, or exposure to N-nitroso compounds. Current research also indicates that mobile phone use does not increase GBM risk, though the effects of long-term use remain under investigation.

Glioblastoma (GBM) is characterized by immune evasion, high tumor heterogeneity, and a relatively immune-privileged CNS environment due to limited antigen-presenting cells and lymphatics, contributing to its poor prognosis. Malignant cells exhibit abnormal proliferation, growth, and angiogenesis driven by numerous genetic and epigenetic mutations, which are crucial for understanding tumor behavior and therapy resistance. GBM arises either as primary tumors from neural stem cell precursors or secondary tumors from mutations in mature neural cells such as astrocytes, with its “multiforme” designation reflecting extensive genotypic diversity. Cellular origins include astrocytes, neural stem cells, and oligodendrocyte precursor cells, while the cancer stem cell (CSC) model highlights hierarchical tumor initiation. Based on genomic and transcriptomic analyses from TCGA, GBM is classified into four subtypes: classical (chromosome 7 amplification, chromosome 10 loss), neural (GABRA1, SLC12A5 expression), proneural (IDH1 mutations), and mesenchymal (CDKN2A and NF1 loss with mesenchymal markers CHI3L1, MET, CD44). Spatially, proneural and neural tumors arise near the subventricular zone, whereas mesenchymal and classical subtypes occur more distally. Additionally, N6-methyladenine (m6A) RNA modification, regulated by specific writer, eraser, and reader enzymes, represents the predominant post-transcriptional modification in GBM, affecting tumor biology.

Glioblastoma diagnosis relies on brain MRI, which typically reveals poorly defined lesions with peripheral ring enhancement from blood-brain barrier disruption, central T1 hypointensity from necrosis, and T2/FLAIR hyperintensity due to surrounding edema. Perfusion-weighted imaging (PWI) demonstrates increased cerebral blood flow from neoangiogenesis, while MR spectroscopy often shows a choline peak. Definitive diagnosis requires histopathological examination, with additional testing recommended for GFAP expression, IDH mutation status, and MGMT promoter methylation to guide prognosis and treatment planning.

Glioblastoma (GBM) treatment is multidisciplinary, combining maximal safe surgical resection with adjuvant radiochemotherapy. Gross total resection, aided by intraoperative imaging, fluorescence guidance, or awake craniotomy, improves survival and functional outcomes. Radiotherapy including conventional, hypofractionated, stereotactic, proton therapy, and tumor-treating fields is often paired with temozolomide, with regimens tailored by age, performance status, and MGMT methylation. Chemotherapy uses alkylating agents, while molecular-targeted therapies focus on EGFR, VEGF, mTOR, and MEK pathways. Emerging approaches include immunotherapies, cancer vaccines, oncolytic viruses, CAR T-cell therapy, nanoparticle-based drug delivery, and AI-driven models for precision diagnosis and monitoring.

"Glioblastoma- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glioblastoma pipeline landscape is provided which includes the disease overview and Glioblastoma treatment guidelines. The assessment part of the report embraces, in depth Glioblastoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Glioblastoma R&D. The therapies under development are focused on novel approaches to treat/improve Glioblastoma.

Glioblastoma Emerging Drugs Chapters

This segment of the Glioblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glioblastoma Emerging Drugs

• XELJANZ: Pfizer

XELJANZ stands out as the first and only oral Janus kinase (JAK) inhibitor to receive approval in the United States across five distinct therapeutic indications. This approval underscores its unique role in targeting multiple immune-mediated conditions, offering patients a convenient oral treatment option where previously such targeted therapies were limited or unavailable. Currently the drug is in Phase III stage of its development for the treatment of Glioblastoma.

• Denifanstat: Sagimet Biosciences / Ascletis Pharmaceuticals

Denifanstat (ASC40) is an investigational, orally administered fatty acid synthase (FASN) inhibitor developed by Sagimet Biosciences, aimed at modulating key lipid metabolism pathways involved in various disease processes. The drug is currently being evaluated across several therapeutic areas, including metabolic diseases, dermatology, and oncology, highlighting its versatile therapeutic potential. ASC40, the compound’s licensed name in China, has been exclusively licensed by Sagimet to Ascletis Pharmaceuticals Co., Ltd. for development and commercialization rights in the Greater China region. This collaboration supports broader global advancement of the molecule. Currently, Denifanstat is in Phase III clinical development for the treatment of Recurrent Glioblastoma.

• LAM561: Laminar Pharma

LAM561 (2-hydroxyoleic acid) is an orally administered synthetic derivative of oleic acid designed to cross the blood-brain barrier and target cancer cells. It acts as an activator of sphingomyelin synthase 1 (SMS1), an enzyme regulating membrane phospholipid balance, particularly sphingolipids. By modifying the lipid composition of cancer cell membranes, LAM561 disrupts the localization and activity of signaling proteins like K-Ras, thereby inactivating key proliferative pathways such as Ras/MAPK, PI3K/AKT/mTOR, and PKC/Cyclin-CDK. This mechanism triggers endoplasmic reticulum stress, cell cycle arrest, and selective cancer cell death, demonstrating efficacy in about half of tested human cancer cell lines and patient samples. Currently, the drug is in Phase II/III stage of its development for the treatment of Glioblastoma.

• TVI-Brain-1: TVAX Biomedical

TVI-Brain-1 is an investigational immunotherapy developed by TVAX Biomedical for the treatment of glioblastoma. It utilizes the TVAX Immunotherapy® platform, which combines a personalized cancer-cell vaccine with adoptive T cell therapy to generate neoantigen-specific T cells that selectively target tumor cells. The therapy has shown encouraging results in early clinical trials, demonstrating improved survival compared to historical controls. Supported by FDA Fast Track Designation and a USD 2 million orphan grant, TVI-Brain-1 is currently being evaluated in Phase II/III clinical trial for the treatment of Glioblastoma Multiforme of Brain.

• Trastuzumab deruxtecan: AstraZeneca/Daiichi Sankyo

Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate (ADC) developed using Daiichi Sankyo’s proprietary DXd technology. It serves as the lead ADC in Daiichi Sankyo’s oncology portfolio and the most advanced program within AstraZeneca’s ADC platform. ADCs are precision cancer therapies that deliver a potent chemotherapy payload to tumor cells through a linker attached to a monoclonal antibody. In this case, trastuzumab deruxtecan combines a HER2-specific antibody with a novel topoisomerase I inhibitor payload connected via a stable tetrapeptide-based linker. Currently the drug is in Phase II stage of its development for the treatment of Glioblastoma.

• SNC109: Shanghai Simnova Biotechnology Co.,Ltd.

SNC109 is a dual-targeted CAR-T cell therapy developed by Shanghai Simnova Biotechnology Co., Ltd. It targets HER2, IL13R?2, EGFR, and EGFRvIII, which are commonly overexpressed in glioblastoma multiforme (GBM) cells. This approach aims to overcome tumor heterogeneity and antigen escape by redirecting T cells to multiple tumor-associated antigens. Currently, the drug is in Phase I stage of its development for the treatment of Recurrent Glioblastoma Multiforme (GBM).

Further product details are provided in the report……..

Glioblastoma: Therapeutic Assessment

This segment of the report provides insights about the different Glioblastoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Glioblastoma
• There are approx. 200+ key companies which are developing the therapies for Glioblastoma. The companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.

• Phases

DelveInsight’s report covers around 220+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glioblastoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Glioblastoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioblastoma drugs.

Glioblastoma Report Insights

• Glioblastoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glioblastoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Glioblastoma drugs?
• How many Glioblastoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioblastoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glioblastoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glioblastoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sapience Therapeutics
• Kazia Therapeutics
• Pfizer
• Laminar Pharmaceuticals
• Sagimet Biosciences
• TVAX Biomedical
• AstraZeneca/Daiichi Sankyo
• MimiVax LLC
• BPGbio
• Polaris Pharma
• BeyondBio
• Acerta Pharma
• Erasca
• Guangzhou Virotech Pharmaceutical
• Compass Therapeutics
• Philogen
• Myosin Therapeutics
• Cantex Pharmaceuticals
• Beijing Pearl Biotechnology
• Inovio Pharmaceuticals
• CNS Pharmaceuticals
• Crimson Biopharm
• TME Pharma
• Accendatech
• JECHO Biopharmaceuticals
• Shanghai Simnova Biotechnology
• Bristol-Myers Squibb
• Sichuan Baili Pharmaceutical
• Aveta Biomics
• Tetragon Biosciences
• Trogenix
• AiVita Biomedical

Key Products

• ST101
• Paxalisib
• XELJANZ
• LAM561
• Denifanstat
• TVI-Brain-1
• Trastuzumab deruxtecan
• SurVaxM
• BPM31510
• Pegargiminase
• BEY1107
• ACP-196
• ERAS-801
• VRT106
• CTX-009
• L19TNF
• MT-125
• Azeliragon
• PLB1001
• INO-5401
• Berubicin
• CM93
• Olaptesed pegol
• ACT001
• JL15003
• SNC109
• BL-B01D1
• APG-157
• GLIX1
• TGX-007
• AV-GBM-1